{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-22-000148","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2022-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.872961+00:00","generated_at":"2026-06-27T12:14:22.902765+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Anavex Life Sciences releases data presentation via webcast; details not disclosed in filing","bullets":["CEO Christopher Missling and CMO Ed Hammond presented data via webcast on February 2, 2022.","Exhibit 99.1 referenced but not included in provided text; content unknown.","No financial or clinical results specified in the 8-K filing.","Investors should review the full presentation for material information."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-22-000148","json":"https://secwatch.observer/filing/0001731122-22-000148.json","markdown":"https://secwatch.observer/filing/0001731122-22-000148.md","text":"https://secwatch.observer/filing/0001731122-22-000148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222000148/0001731122-22-000148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222000148/e3468_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T12:14:22.902765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}